Cargando…

The Real-Life Effectiveness and Care Patterns of Diabetes Management Study for Balkan Region (Slovenia, Croatia, Serbia, Bulgaria): A Multicenter, Observational, Cross-Sectional Study

INTRODUCTION: Recent large randomized controlled trials highlighted the clinical significance of hypoglycemic episodes in the treatment of diabetes. The present survey was conducted to provide information from real-life practice on the incidence of hypoglycemia in type 2 diabetic patients treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Majanovic, Sanja Klobucar, Janez, Andrej, Lefterov, Ivaylo, Tasic, Sanja, Cikac, Tatjana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544624/
https://www.ncbi.nlm.nih.gov/pubmed/28695415
http://dx.doi.org/10.1007/s13300-017-0288-x
_version_ 1783255276094226432
author Majanovic, Sanja Klobucar
Janez, Andrej
Lefterov, Ivaylo
Tasic, Sanja
Cikac, Tatjana
author_facet Majanovic, Sanja Klobucar
Janez, Andrej
Lefterov, Ivaylo
Tasic, Sanja
Cikac, Tatjana
author_sort Majanovic, Sanja Klobucar
collection PubMed
description INTRODUCTION: Recent large randomized controlled trials highlighted the clinical significance of hypoglycemic episodes in the treatment of diabetes. The present survey was conducted to provide information from real-life practice on the incidence of hypoglycemia in type 2 diabetic patients treated with sulfonylureas. METHODS: This multicenter, observational, cross-sectional study collected data on incidence of side effects of sulfonylurea-based therapy in type 2 diabetic patients in four countries of the Balkan region (Slovenia, Croatia, Serbia, Bulgaria) from October 2014 to June 2015. RESULTS: Of the 608 who participated in the study, 573 patients (mean age 67.2 years, mean body mass index 29.9 kg/m(2)) met the inclusion/exclusion criteria. More than 90% of the patients were treated with the newer generation sulfonylureas—gliclazide or glimepiride—either as monotherapy or as dual therapy in combination with metformin. In total, 210 patients (36.6%) reported hypoglycemic episode(s) in the last 6 months. Mild episodes were reported by 132 patients (62.8%), moderate by 66 (31.2%), severe by 8 patients (4.0%), and very severe by 4 patients (2%), respectively. Overall, 171 patients (28.2%) reported body weight increase during the previous year. The mean reported body weight gain in this group of patients was 4.2 kg (SD 2.7, median 3). Among them, 68.1% gained less than 5 kg, 25.0% gained 5–9 kg, and the rest gained more than 10 kg. CONCLUSION: Although newer generation sulfonylureas are generally considered safe in terms of hypoglycemia, our data indicates their use is associated with substantial risk of hypoglycemia and weight gain. Clinicians should be mindful of these findings when prescribing SUs and inform patients about the risk of hypoglycemia. FUNDING: Merck Sharp & Dohme. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-017-0288-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5544624
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-55446242017-08-18 The Real-Life Effectiveness and Care Patterns of Diabetes Management Study for Balkan Region (Slovenia, Croatia, Serbia, Bulgaria): A Multicenter, Observational, Cross-Sectional Study Majanovic, Sanja Klobucar Janez, Andrej Lefterov, Ivaylo Tasic, Sanja Cikac, Tatjana Diabetes Ther Original Research INTRODUCTION: Recent large randomized controlled trials highlighted the clinical significance of hypoglycemic episodes in the treatment of diabetes. The present survey was conducted to provide information from real-life practice on the incidence of hypoglycemia in type 2 diabetic patients treated with sulfonylureas. METHODS: This multicenter, observational, cross-sectional study collected data on incidence of side effects of sulfonylurea-based therapy in type 2 diabetic patients in four countries of the Balkan region (Slovenia, Croatia, Serbia, Bulgaria) from October 2014 to June 2015. RESULTS: Of the 608 who participated in the study, 573 patients (mean age 67.2 years, mean body mass index 29.9 kg/m(2)) met the inclusion/exclusion criteria. More than 90% of the patients were treated with the newer generation sulfonylureas—gliclazide or glimepiride—either as monotherapy or as dual therapy in combination with metformin. In total, 210 patients (36.6%) reported hypoglycemic episode(s) in the last 6 months. Mild episodes were reported by 132 patients (62.8%), moderate by 66 (31.2%), severe by 8 patients (4.0%), and very severe by 4 patients (2%), respectively. Overall, 171 patients (28.2%) reported body weight increase during the previous year. The mean reported body weight gain in this group of patients was 4.2 kg (SD 2.7, median 3). Among them, 68.1% gained less than 5 kg, 25.0% gained 5–9 kg, and the rest gained more than 10 kg. CONCLUSION: Although newer generation sulfonylureas are generally considered safe in terms of hypoglycemia, our data indicates their use is associated with substantial risk of hypoglycemia and weight gain. Clinicians should be mindful of these findings when prescribing SUs and inform patients about the risk of hypoglycemia. FUNDING: Merck Sharp & Dohme. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-017-0288-x) contains supplementary material, which is available to authorized users. Springer Healthcare 2017-07-10 2017-08 /pmc/articles/PMC5544624/ /pubmed/28695415 http://dx.doi.org/10.1007/s13300-017-0288-x Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Majanovic, Sanja Klobucar
Janez, Andrej
Lefterov, Ivaylo
Tasic, Sanja
Cikac, Tatjana
The Real-Life Effectiveness and Care Patterns of Diabetes Management Study for Balkan Region (Slovenia, Croatia, Serbia, Bulgaria): A Multicenter, Observational, Cross-Sectional Study
title The Real-Life Effectiveness and Care Patterns of Diabetes Management Study for Balkan Region (Slovenia, Croatia, Serbia, Bulgaria): A Multicenter, Observational, Cross-Sectional Study
title_full The Real-Life Effectiveness and Care Patterns of Diabetes Management Study for Balkan Region (Slovenia, Croatia, Serbia, Bulgaria): A Multicenter, Observational, Cross-Sectional Study
title_fullStr The Real-Life Effectiveness and Care Patterns of Diabetes Management Study for Balkan Region (Slovenia, Croatia, Serbia, Bulgaria): A Multicenter, Observational, Cross-Sectional Study
title_full_unstemmed The Real-Life Effectiveness and Care Patterns of Diabetes Management Study for Balkan Region (Slovenia, Croatia, Serbia, Bulgaria): A Multicenter, Observational, Cross-Sectional Study
title_short The Real-Life Effectiveness and Care Patterns of Diabetes Management Study for Balkan Region (Slovenia, Croatia, Serbia, Bulgaria): A Multicenter, Observational, Cross-Sectional Study
title_sort real-life effectiveness and care patterns of diabetes management study for balkan region (slovenia, croatia, serbia, bulgaria): a multicenter, observational, cross-sectional study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544624/
https://www.ncbi.nlm.nih.gov/pubmed/28695415
http://dx.doi.org/10.1007/s13300-017-0288-x
work_keys_str_mv AT majanovicsanjaklobucar thereallifeeffectivenessandcarepatternsofdiabetesmanagementstudyforbalkanregionsloveniacroatiaserbiabulgariaamulticenterobservationalcrosssectionalstudy
AT janezandrej thereallifeeffectivenessandcarepatternsofdiabetesmanagementstudyforbalkanregionsloveniacroatiaserbiabulgariaamulticenterobservationalcrosssectionalstudy
AT lefterovivaylo thereallifeeffectivenessandcarepatternsofdiabetesmanagementstudyforbalkanregionsloveniacroatiaserbiabulgariaamulticenterobservationalcrosssectionalstudy
AT tasicsanja thereallifeeffectivenessandcarepatternsofdiabetesmanagementstudyforbalkanregionsloveniacroatiaserbiabulgariaamulticenterobservationalcrosssectionalstudy
AT cikactatjana thereallifeeffectivenessandcarepatternsofdiabetesmanagementstudyforbalkanregionsloveniacroatiaserbiabulgariaamulticenterobservationalcrosssectionalstudy
AT majanovicsanjaklobucar reallifeeffectivenessandcarepatternsofdiabetesmanagementstudyforbalkanregionsloveniacroatiaserbiabulgariaamulticenterobservationalcrosssectionalstudy
AT janezandrej reallifeeffectivenessandcarepatternsofdiabetesmanagementstudyforbalkanregionsloveniacroatiaserbiabulgariaamulticenterobservationalcrosssectionalstudy
AT lefterovivaylo reallifeeffectivenessandcarepatternsofdiabetesmanagementstudyforbalkanregionsloveniacroatiaserbiabulgariaamulticenterobservationalcrosssectionalstudy
AT tasicsanja reallifeeffectivenessandcarepatternsofdiabetesmanagementstudyforbalkanregionsloveniacroatiaserbiabulgariaamulticenterobservationalcrosssectionalstudy
AT cikactatjana reallifeeffectivenessandcarepatternsofdiabetesmanagementstudyforbalkanregionsloveniacroatiaserbiabulgariaamulticenterobservationalcrosssectionalstudy